ESTRO 2025 - Abstract Book

S610

Clinical - Breast

ESTRO 2025

Conclusion: OMDT for highly-selective nOMBC patients is feasible and safe in real-world setting. The benefit of adding OMDT in HR-ve subgroup of nOMBC patients may be questionable. HR+ve patients with limited volume nOMBC should be considered for OMDT as they have better prognosis. Further studies should be aimed at optimizing OMDT and escalating systemic therapy to reduce subsequent distant metastases in this cohort.

Keywords: nodal-oligometastases, curative therapy, outcomes